Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers
While resistance to antiviral drugs can hinder their clinical use, understanding resistance mechanisms can illuminate how these drugs and their targets act. We studied a substitution in the human cytomegalovirus (HCMV) DNA polymerase that confers resistance to a leading anti-HCMV drug, ganciclovir.
Guardado en:
Autores principales: | Han Chen, Jessica L. Lawler, David J. Filman, James M. Hogle, Donald M. Coen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0f46903a19ac46bc9b2f75df1b75364b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Structural basis for polymerase η–promoted resistance to the anticancer nucleoside analog cytarabine
por: Olga Rechkoblit, et al.
Publicado: (2018) -
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance
por: Daisy Yan, et al.
Publicado: (2021) -
Antiviral Drug Research Proposal Activity
por: Lisa Injaian, et al.
Publicado: (2011) -
HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.
por: Max von Kleist, et al.
Publicado: (2012) -
Antiviral Drug Discovery To Address the COVID-19 Pandemic
por: Douglas D. Richman
Publicado: (2020)